An Audit of Anticoagulation Practice among UK Cardiothoracic Consultant Surgeons following Valve Replacement/Repair Department of Thoracic Surgery, Glenfield Hospital, Leicester, Department of Cardiothoracic Surgery, Wythenshawe Hospital, Manchester, UK |
|||||||
Background and aim of the study: In 1998, the
American College of Cardiology and The American Heart Association (ACC/AHA)
published guidelines for the postoperative anticoagulation of patients
who have undergone heart valve replacement. The American College of Chest
Physicians made similar recommendations in 2001. The present survey was
conducted to review anticoagulation practice among UK consultant cardiac
surgeons, and to assess compliance with these guidelines. |
valve replacement (MVR). Temporary (£3 months) warfarin
is used by 47% (46/97) of consultants after bioprosthetic AVR and by
63% (54/86) after bioprosthetic MVR. Some 64% (52/81) of consultants
use warfarin after mitral valve repair, when an annuloplasty ring is
inserted. This was always temporary (£6 months). Aspirin is used
long term by 54% (44/82) of consultants after mitral valve repair. |
||||||
|
|||||||